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Background: Chronic rhinosinusitis (CRS) is a heterogeneous group of inflammatory sinonasal disorders with key defin-
ing symptoms, but traditionally separated into phenotypes by clinical/endoscopic findings. It is not known whether the two
phenotypes have differing socioeconomic, comorbidity, and lifestyle differences. This analysis of the Chronic Rhinosinusitis Epi-
demiology Study (CRES) database sought to analyze any key differences in the socioeconomic variables between those with
CRS with nasal polyps (CRSwNPs) and those without nasal polyps (CRSsNPs). We also sought to analyze differences in com-
orbidities, lifestyle, and quality of life.
Methods: Patients with a confirmed diagnosis of CRS in secondary and tertiary care outpatient settings in the UK were
invited to participate in a questionnaire-based case–control study. Variables included demographics, socioeconomic factors,
comorbidities, lifestyle factors, and health-related quality of life (HRQoL) (level 3 evidence).
Results: A total of 1204 patients’ data were analyzed: 553 CRSsNP and 651 CRSwNP participants. The key socioeconomic
variables did not demonstrate any notable differences, nor did lifestyle variables other than alcohol consumption being higher
in those with CRSwNP (P = .032), but the latter was not significant after adjusting for age and sex. Aside from confirmation of
asthma being more common in CRSwNP, it was notable that this group complained less of upper respiratory tract infections
(URTIs), and CRSsNP participants showed evidence of worse HRQoL scores in respect of body pain (P = .001).
Conclusions: Patients with CRSwNP experience higher rates of asthma and lower rates of URTIs; patients with CRSsNP
have worse body pain scores. Otherwise, there are no demonstrable significant socioeconomic, comorbidity, lifestyle, or quality
of life differences between the two phenotypes.
Level of evidence: 3
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INTRODUCTION
Background
Chronic rhinosinusitis (CRS) is a common condition
of the upper respiratory tract1 with poor quality of life
and known associations with the lower respiratory tract.2
It is known that socioeconomic deprivation can be associ-
ated with a higher prevalence of asthma and poorer lung
function.3,4 The Chronic Rhinosinusitis Epidemiology
Study (CRES) was designed to distinguish differences in
socioeconomic status, geography, medical/psychiatric
comorbidity, lifestyle, and overall quality of life between
patients with CRS and healthy controls. Our previous
analysis of the CRES data set did not show evidence of
any socioeconomic disparity between CRS cases and
controls,5 and this was corroborated by a recent system-
atic review that found smoking was the only key associa-
tion.6 However, given the differing rates of asthma in the
two main phenotypes of CRS,2 it is possible that dispar-
ities between these two phenotypes exist and this had not
been explored in the original analyses.5 Smoking does not
appear to differ between phenotypes in our both recent
analysis and a larger data set.7,8 Other studies have con-
sidered socioeconomic variables but have not usually com-
pared the two main phenotypes6,9 The latter review by
Geramas et al.6 showed an association in some studies
between CRS and low socioeconomic status but not all
studies relied on clinicians confirming the diagnosis of
CRS, as is the case in the CRES.5 As we had already con-
trasted controls and CRS participants, it was determined
that a separate comparative analysis of the two main
phenotypes was needed.
Aims and Objectives
Previous analyses of the CRES data set have consid-
ered quality of life, mood disturbances, rates of surgery
and revision surgery, use of medication, rates of allergy,
asthma, aspirin sensitivity and Eustachian tube dysfunc-
tion, and the role of dietary salicylates and smoking, as
well as qualitative analyses.2,7,10–18 The aim of the analy-
sis of the CRES database presented here was to specifi-
cally compare these variables between the two
phenotypes of CRS, as this was not a feature of our origi-
nal analysis,5 and for any variables not examined in any
of the subsequent analyses that appeared worthy of closer
examination including comorbidities.
MATERIALS AND METHODS
This study has been reported in accordance with the
Strengthening the Reporting of Observational studies in Epide-
miology (STROBE) statement guidelines for the reporting of
observational studies. STROBE guidelines were developed fol-
lowing an initiative of epidemiologists, methodologists, statisti-
cians, researchers, and journal editors in 2004 to ensure rigorous
reporting and assessment of data.19 The study was sponsored by
the University of East Anglia (UEA) and funded by the Anthony
Long and Bernice Bibby Trusts. Ethical approval was granted by
the Oxford C Research Ethics Committee (Ref: 07/H0606/100).
Study Design
The CRES was a prospective, questionnaire-based, case–
control study conducted between October 2007 and September
2013 at 30 tertiary/secondary care sites across the United King-
dom. Patients with diagnosed CRS alongside healthy control sub-
jects were asked to complete a single, study-specific
questionnaire, capturing a variety of demographic and socioeco-
nomic variables, environmental exposures, and medical com-
orbidities (see Supporting Information, Appendix 1, in the online
version of this article). As the healthy control participants are
not part of this analysis, the details of their involvement are not
considered further here.
Participants and Data Sources
Prospective participants were identified for recruitment at
ENT outpatient clinics at 30 participating centers. Patients
with CRS were examined by an ENT clinician and classified into
CRS phenotypes (CRSwNPs, CRSsNPs, or allergic fungal
rhinosinusitis (AFRS) as per European Position Paper on Sinusi-
tis and Nasal Polyps (EPOS) 2012 criteria20 (see Section 2.2.1).
Questionnaires were completed during the clinic visit or taken
home to be completed and returned by prepaid post. No partici-
pant identifiable data were captured, therefore consent was not
required although it was implied through return of the question-
naire. Returned questionnaires were scanned and the data were
imported into an electronic database in Microsoft Excel. Records
in the database were compared to physical copies of the question-
naires by two members of the research team to ensure accuracy
and consistency between the two.
All CRS participants were required to meet the inclusion/
exclusion criteria outlined later.
CRS participants
Inclusion criteria. Criteria for diagnosis of CRS with
or without polyps (EPOS 2012 guidelines—as were relevant at
the time of study).20
At least two symptoms must be present for at least
12 weeks and include the following:
• One of either nasal blockage/obstruction/congestion and/or
nasal discharge (anterior/posterior nasal drip)
• Either facial pain/pressure and/or reduction or loss of sense of
smell
and in addition:
• Endoscopic signs: polyps and/or mucopurulent discharge pri-
marily from middle meatus and/or edema/mucosal obstruction
primarily in middle meatus
• CT changes: mucosal changes within the ostiomeatal complex
and/or sinuses
Patients were then classified as having CRS without polyps
(CRSsNPs), CRS with nasal polyps (CRSwNPs), or AFRS;
patients with the latter were not included in this analysis.
Exclusion criteria
• Patients/controls unable to comprehend written English.
• Patients/controls under the age of 18 years.
Quantitative Variables and Bias
The detailed questionnaire can be seen in Supporting Informa-
tion, Appendix 1, in the online version of this article). The variables
considered here in this updated analysis include the following:
1. The presence of comorbidities including asthma, chronic
obstructive pulmonary disease (COPD), bronchiectasis,
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diabetes, hypothyroidism, autoimmune diseases, immunodefi-
ciency and ciliary dysmotility; data on the frequency of URTIs
were also collected using the question: “How often do you get
a cold or sore throat in the space of 1 year?”
2. Quality of life as recorded by the domains of the SF-36.
3. Socioeconomic variables including mean index of multiple dep-
rivation (IMD), mean household income, household occupancy,
and education level.
4. Lifestyle factors including smoking and alcohol.
5. Environmental factors including urban or nonurban domestic
home location and occupational setting (indoor/outdoor/unclear).
For the latter, the research team reviewed the list of occupations
and classified them as either “indoor” (where the setting would
be predominately indoors, e.g., secretary), outdoor (where the
setting would be predominantly outdoors, e.g., tree surgeon), or
unclear where a judgment could not easily be made.
Sample Size Calculation
The sample size calculation was based on the original
primary outcome of the study, which was to look for common
associations between socioeconomic factors between CRS
participants and controls.5 In order for the study to have
80% power to detect a difference of 10% in “low social class”
between controls and CRS participants, assuming a 30% rate in
the CRS participants, with approximately 5 CRS participants to
1 control patient, 965 CRS participants and 193 controls were
required. The context of this can be found in our previous
publication.5
Statistical Methods
Patient demographics were summarized by CRS phenotype
status using mean and SD for continuous variables and the
number and percentage for categorical variables. For the compar-
isons between the two phenotypes, we planned the following
analyses:
1. Comorbidities—comparisons using logistic regression










Note that psychiatric comorbidity has already been consid-
ered previously.15
2. Quality of life: Comparing the mean SF-36 score, its sub-
scales (vitality, physical function, bodily pain, general health per-
ceptions, physical role functioning, emotional role functioning,
social role functioning, and mental health) and its summary
score (physical health and mental health) between the two
groups using regression, adjusting for age and sex.
3. Socio-economic status:
• Mean index of multiple deprivation (IMD) using regression,
adjusting for age and sex
• Mean household income using regression, adjusting for age
and sex
• Median household occupancy using a Mann–Whitney test
• Highest education level achieved using a chi-squared test
for individual levels and an odds ratio for grouped levels
of GSCE/A-level (secondary school level qualifications) and
degree/higher degree (higher education level qualifications).
4. Lifestyle factors were compared using multinomial logis-
tic regression adjusting for age and sex
• Comparison of alcohol consumption
• Comparison of smoking rates
5. Environmental exposure was compared using a chi-
squared test
• Comparison of the percentage of people who live in a village
(as a proxy for being less exposed to environmental pollution)
• Comparison of the percentage of people who work outdoors
(as judged by occupation)
All analyses were conducted using Stata MP 16.0.
RESULTS
Study Participants
A total of 1535 questionnaires were returned with
1470 considered eligible for inclusion after removal of
duplicates and questionnaires with missing data; only
CRSwNP and CRSsNP cases were included in this analy-
sis (see Fig. 1). This analysis is therefore based on the
1204 CRS participants who completed the relevant parts
of the questionnaire. The overall response rate of those
identified to take part in the study was 66% of those
distributed.
Descriptive Data
For the purpose of this analysis, participants with
AFRS were not analyzed due to smaller numbers of cases
in the database. As such, there were 553 participants
with CRSsNPs and 651 participants with CRSwNPs. The
mean age of CRSsNP participants was 52 years (range
18–84 years) and of CRSwNP participants was 56 years
(range 18–102 years). CRSsNP and CRSwNP participants
were 53% and 31% females, respectively; 65 and 77 partic-
ipants in those two phenotypes, respectively, did not
Fig. 1. Participant flow diagram. [Color figure can be viewed in the
online issue, which is available at www.laryngoscope.com.]
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declare their sex. There were 80 (7%) of participants iden-
tifying aspirin sensitivity.
Primary Outcome Data and Main Results
Comorbidities. There were significant differences
in asthma, with those with CRSwNPs having more than
three times the odds of having asthma compared to those
with CRSsNPs (Table I).2 Other statistically significant
differences included autoimmune disorders being more
common in CRSsNP and with CRSwNP patients more
likely to say they “never” or “seldom” suffered an URTI
(autoimmune disorders reported are listed in Table II).
Quality of Life
Most of the domains showed a statistically signifi-
cant difference in the unadjusted analysis; however, only
a difference in body pain (P = .001) between those with
polyps and those without remained between the groups
after adjusting for age and sex (Table III). Therefore,
worse scores were observed in those with CRSsNP for
body pain only.
Socioeconomic Status
There was no evidence of a difference in deprivation
(P = .787), income (P = .424), household occupancy
(P = .43), or educational qualification (P = .251) between
those with polyps and those without (Table IV). Figure 2
demonstrates the distribution of household income across
both groups.
Lifestyle Variables
The comparison of the two phenotypes showed no evi-
dence of a difference in smoking (P = .25) or home location
(P = .12), but did show a difference in alcohol consumption,
with CRSwNP participants likely to drink more alcohol
than those with CRSsNP (P = .032) (Table V).
DISCUSSION
Key Results
No demonstrable differences were found for the key
socioeconomic variables between the two groups, nor were
there any differences in lifestyle variables other than alco-
hol consumption being higher in those with CRSwNP.
Aside from confirmation of asthma being more common in
CRSwNP, it was notable that this group complained less of
TABLE I.
Comparison of Comorbidities Between CRSsNP and CRSwNP.
Comorbidity
CRSsNP (n = 553) CRSwNPs (n = 651)
Unadjusted Adjusted
N (%) N (%) OR (95% CI) P-value OR (95% CI)† P-value
Asthma 117 (21.2%) 303 (46.9%) 3.29 (2.55, 4.25) <.001 3.67 (2.70, 4.98) <.001
COPD 19 (3.4%) 35 (5.4%) 1.61 (0.91, 2.52) .102 1.26 (0.64, 2.47) .500
Bronchiectasis 30 (5.4%) 43 (6.7%) 1.24 (0.77, 2.02) .375 0.94 (0.55, 1.61) .826
Diabetes 31 (5.6%) 34 (5.3%) 0.94 (0.57, 1.54) .794 0.66 (0.38, 1.16) .147
Hypothyroidism 30 (5.4%) 32 (5.0%) 0.91 (0.55, 1.52) .718 1.30 (0.74, 2.28) .370
Immunodeficiency 14 (2.5%) 15 (2.3%) 0.92 (0.44, 1.92) .817 1.16 (0.50, 2.70) .728
Autoimmune disorder 37 (6.7%) 25 (3.9%) 0.56 (0.33, 0.95) .030 0.51 (0.28, 0.93) .029
Ciliary dysmotility 4 (0.7%) 0 (0.0%) .045‡
Number of colds per year
Never 14 (2.5%) 23 (3.6%) <.001
Seldom 216 (39.2%) 309 (48.4%)
Often 196 (35.6%) 201 (31.5%)
Frequent 125 (22.7%) 106 (16.6%)
Bold values indicates significant p-value (<0.05).
†Adjusted for age, sex, asthma, and aspirin sensitivity.
‡Fisher’s exact test.
Table II.
Autoimmune disorders by phenotype when details reported
(numbers represent frequency of the disorders not the number of
participants as some participants reported more than 1 disorder);
not all participants specified details in the free text.
Autoimmune disorder
specified in free text
Frequency in
CRSsNP (n = 37)
Frequency in








Rheumatoid arthritis 4 4
Sarcoidosis 2
Sjogren’s syndrome 2 1
Ulcerative colitis 1
Vasculitis (ANCA +ve) 1 1
Vitiligo 1
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URTIs. CRSsNP participants showed evidence of worse
(lower) health-related quality of life (HRQoL) scores in
respect of body pain. The difference in alcohol consumption
may be explained by the gender differences. In the United
Kingdom, men consume more alcohol than women. The
2018 Health Survey for England showed that the mean
male weekly alcohol consumption in units was 15.5 while
for females it was 9.21 The same survey also found that
14% of male responders were teetotal compared to 21% of
female responders. Our data show that males are signifi-
cantly more likely to suffer from CRSwNP than females.
Interpretation
CRES is the largest epidemiological study of CRS
and the first study since the 2001 Sinonasal Audit22 to
collect detailed information on socioeconomic variables in
the United Kingdom. As mentioned earlier, a systematic
review in 2018 concluded that smoking, social depriva-
tion, and low socioeconomic level appear to have a direct
correlation with rhinosinusitis.6 They also concluded that
education level, and exercise and diet appear to have a
more complex relationship with CRS. In the Korean
KNHANES study, CRSwNP was more prevalent in rural
areas and with a lower level of education, obesity,
increased amounts of smoking and alcohol consumption,
and comorbid asthma.8 It is possible that some of these
differences are accounted for by ethnic differences in the
underlying pathophysiology.23
A small study (n = 186) comparing patients with
AFRS and CRS found that the CRS cases were predomi-
nantly white and older at the time of diagnosis with
Table III.
Comparison of quality of life between CRSSsNP and CRSwNP.
Comorbidity
CRSsNP (n = 553) CRSwNPs (n = 651)
Unadjusted Adjusted†
N (%) N (%) Mean difference (95% CI) P-value Mean difference (95% CI) P-value
Vitality, mean (SD) 50.97 (23.35) 54.81 (22.98) 3.84 (1.17, 6.51) .005 1.64 (−1.29, 4.57) .273
Physical function, mean (SD) 71.07 (28.26) 72.76 (26.31) 1.70 (−1.44, 4.84) .289 2.30 (−1.12, 4.84) .187
Body pain, mean (SD) 63.34 (27.14) 70.66 (25.89) 7.32 (4.26, 10.37) <.001 5.77 (2.40, 9.13) .001
General health, mean (SD) 53.13 (22.97) 53.45 (23.16) 0.31 (−2.35, 2.97) .818 −0.77 (−3.71, 2.17) .607
Role physical, mean (SD) 67.48 (40.86) 71.19 (39.61) 3.71 (−0.92,8.35) .0016 2.47 (−2.68, 7.62) .347
Role emotional, mean (SD) 78.13 (37.05) 82.87 (33.51) 4.74 (0.68, 8.79) .022 2.71 (−1.76, 7.18) .234
Social functioning, mean (SD) 73.47 (27.76) 78.19 (25.18) 4.72 (1.68, 7.77) .002 2.96 (−0.38, 6.30) .083
Mental health, mean (SD) 69.58 (19.82) 72.72 (18.23) 3.14 (0.95, 5.33) .005 0.81 (−1.52, 3.15) .495
Physical health, mean (SD) 61.14 (22.40) 64.47 (21.05) 3.33 (0.83, 5.83) .009 2.23 (−0.52, 4.97) .112
Mental health, mean (SD) 65.07 (20.81) 68.40 (19.47) 3.33 (1.01, 5.65) .005 1.46 (−1.05, 3.96) .254
TOTAL SF36 Score, mean (SD) 65.92 (21.41) 69.61 (19.63) 3.70 (1.34, 6.06) .002 2.24 (−0.33, 4.81) .088
Bold values indicates significant p-value (<0.05).
†Adjusted for age and sex.
Table IV.
Comparison of socio-economic status between CRSSsNP and CRSwNP.
Variable
CRSsNP (n = 553) CRSwNPs (n = 651)
Unadjusted Adjusted†
N (%) N (%) Mean difference (95% CI) P-value Mean difference (95% CI) P-value
IMD score 16.49 (10.60) 16.66 (9.88) 0.17 (−1.06, 1.40) .787 0.18 (−1.20, 1.56) .795
Income 39426.13 (30567.75) 41203.37 (30478.51) 1777.23 (−2580.13, 6134.59) .4241 2467.90 (−2277.50, 7213.29) .3081
Qualifications
GCSE 108 (27.6%) 125 (26.6%) .2512
A-level 36 (9.2%) 51 (10.9%)
NVQ 65 (16.6%) 78 (16.6%)
Degree 135 (34.5%) 138 (29.4%)
Higher degree 46 (11.8%) 76 (16.2%)
Qualification (grouped)
GCSE/A-level 144 (36.9%) 176 (37.6%) 1 1
NVQ/degree/higher
degree
246 (63.1%) 292 (62.4%) 0.97 (0.74, 1.28)‡ .837 1.01 (0.74, 1.38)‡ .946
Based on a chi-squared test.
†Adjusted for age and gender based on a nonparametric bootstrap with 10,000 replications.
‡Odds ratio (95% CI).
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higher income levels. They found no associations between
disease severity, socioeconomic status, and demographic
factors within the CRS groups.24 In a North American
study published in 2019, Beswick et al. reported that
their analysis of 392 patients showed that medical insur-
ance status and male gender were significantly associated
with worse smell test scores, and also that higher house-
hold income and lower age led to better outcomes on
HRQoL scores (SNOT-22) following sinus surgery.25 In
this study, 36% of the cases were CRS with nasal polyps
(CRSwNP) and 37% reported asthma. Differing findings
and differing diagnostic and sampling methods across
various studies and healthcare systems suggest that the
true picture has yet to be clarified.
Although our CRES study has not demonstrated any
evidence that socioeconomic deprivation is a risk factor for
CRS or either of the two main phenotypes, other related
work on the cost of managing CRS has shown higher out-
of-pocket expenditure, primary care and secondary care
























GBP (pounds sterling £)
Fig. 2. A histogram of household income by group. [Color figure can be viewed in the online issue, which is available at www.
laryngoscope.com.]
Table V.
Comparison of life-style variables between CRSSsNP and CRSwNP.
Variable
CRSsNP (n = 553)
N (%)
CRSwNPs (n = 651)
N (%) P-value† RR (95% CI) P-value‡ RR (95% CI) P-value§
Alcohol (units/wk) None 196 (35.8%) 180 (28.1%) .032 1
1 to 10 269 (49.1%) 342 (53.4%) 1.38 (1.07, 1.79) .013 1.23 (0.92, 1.66) .155
11 to 20 73 (13.3%) 107 (16.7%) 1.60 (1.11, 2.29) .011 1.13 (0.75, 1.69) .567
>20 10 (1.8%) 11 (1.7%) 1.20 (0.50, 2.89) .688 0.69 (0.25, 1.88) .468
Smoke (cigarettes/d) None 470 (86.1%) 574 (89.7%) .25 1 1
1 to 10 46 (8.4%) 41 (6.4%) 0.73 (0.47, 1.13) .159 0.96 (0.58, 1.59) .883
11 to 20 25 (4.6%) 19 (3.0%) 0.62 (0.34, 1.14) .127 0.58 (0.29, 1.18) .134
>20 5 (0.9%) 6 (0.9%) 0.98 (0.30, 3.24) .977 1.16 (0.31, 4.28) .827
Living location Village 195 (37.9%) 222 (35.7%) .12
Suburbs 160 (31.1%) 229 (36.9%)
Urban 159 (30.9%) 170 (27.4%)
Occupation Indoor 354 (70.2%) 422 (70.9%) .96
Outdoor 20 (4.0%) 24 (4.0%)
Unclear 130 (25.8%) 149 (25.0%)
†Based on a chi-squared test.
‡Unadjusted.
§Adjusted for age and sex.
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without CRS.26 This study estimated an annual average
out of pocket expenses of £304.84 secondary to CRS over
3 months, with a 5.3-fold greater spending on over-the-
counter medication when compared to the general population
and an association with an average 18.7 missed workdays
per year. For those in lower socioeconomic groups, they
are more likely to be disadvantaged by this implication.
This effect appears to have been more pronounced in a
private healthcare system25 but may be less apparent in
the National Health Service where direct health care is
free at the point of service, excluding prescription costs
(England not Scotland).
Although the initial analysis showed that CRSwNP
participants overall reported higher rates of alcohol con-
sumption than those with CRSsNP, when stratified by
level of alcohol consumption (mild and moderate con-
sumption), this significance did not persist after adjusting
for age and sex. This association requires further investi-
gation to better understand any link that might be pre-
sent and may perhaps be more discernible when future
studies compare endotypes instead of phenotypes.
In terms of the differences in reporting URTIs, Wu
et al. elucidated the difficulties in defining acute exacerba-
tions of CRS27 and highlighted that others had used various
metrics to measure this including the number of patient-
reported “sinus infections,” CRS-related antibiotic courses,
and CRS-related oral corticosteroid courses.28–30 These are
of course subjective metrics on the part of the patient and
clinician, and in practice, it will be difficult to separate viral
URTIs from bacterial episodes. Evidence from a large data
set shows that in a primary care setting in the United King-
dom, 46% of CRS patients had received an antibiotic pre-
scription within 5 days of their diagnosis, with 9% are
estimated to have had 5 or more antibiotics over 5 years.31
It is possible that the CRSsNP groups tend to report an
exacerbation of their CRS as an URTI more often than the
CRSwNP group, but it is not clear why that might be.
With respect to the worse body pain scores, these data
are perhaps not surprising given that a previous analysis of
the CRES data showed higher scores in the facial domain
of the SNOT-22 in CRSsNP, particularly with respect to
facial pain that is less prominent in CRSwNP cases.15 It is
likely that this correlates with the higher rates of depres-
sion and anxiety that were evident in the CRSsNP partici-
pants. Talat et al. found similar comparisons between the
two phenotypes but noted that CRSwNP patients had lower
levels of symptom control for every incremental increase in
symptom burden and suggested that this was due to
greater sensitivity or intolerance to CRS symptoms.32
Limitations
The CRES study design has certain limitations,
although the diagnosis was made by a clinician, the
remaining data were self-reported and may therefore pre-
dispose to recall bias. Second, although we collected infor-
mation on household occupancy, we did not collect
information on the number of bedrooms and the potential
for overcrowding. In asthma, overcrowding has been
shown to have a positive33 correlation and a negative34
correlation with respiratory symptoms with no clear
relationship in other studies,35 so there is no clear rela-
tionship in the lower respiratory tract. Our study has also
sampled a mainly British White ethnic demographic and
may not fully reflect the wider population in the United
Kingdom today, but our data do represent a good spread
of the socioeconomic spectrum.5
Generalizability
CRES is a cross-sectional UK-based study incorporat-
ing a variety of the CRS population from across the coun-
try presenting to secondary care. The CRES study does
not necessarily capture the whole CRS spectrum as mild
sufferers may be managed by primary care alone and may
therefore be underrepresented. In contrast to other stud-
ies, CRS was diagnosed by ENT specialists according to
accepted diagnostic guidelines (EPOS 2012) (16); other
existing studies have relied on self-diagnosis and/or used
different criteria making direct comparisons with the exis-
ting literature more complicated. Although we realize
EPOS20201 has now superseded EPOS2012, the former
was relevant at the time of the study being conducted. In
the current era making comparisons between endotypes
such as those with or without type 2 mediated inflamma-
tion may provide further clinical relevance, but for now
these are perhaps not adequately defined.
CONCLUSION
British patients with CRSwNP experience higher
self-reported rates of asthma and lower rates of URTIs;
patients with CRSsNP have worse body pain scores.
Other comparisons for comorbidity, lifestyle, and environ-
mental factors did not show any significant differences. In
the future, as endotyping replaces the current phenotypes
and means of sampling larger sections of the populations
become easier, it will be useful to revisit these findings
through further epidemiological study.
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